BioCryst Pharma (BCRX) Reports Q4 Loss of $0.40/sh
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.78 --0%
EPS Growth %: -43.8%
Financial Fact:
Interest expense: -1.47M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -43.8%
Financial Fact:
Interest expense: -1.47M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), versus ($0.34) reported last year. Revenue for the quarter came in at $47.2 million, versus $4 million reported last year.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Oppenheimer Starts Collegium Pharmaceutical (COLL) at Outperform
- Oppenheimer Starts Amneal Pharmaceuticals (AMRX) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
